SCHEMBL1007936

SCHEMBL1007936

NC(=O)c1ccc2c(c1)C=CC=CN2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.37
SIRT2 Q8IXJ6 1/20 0.35
PARP1 P09874 8/20 0.35
TSHR P16473 2/20 0.35
PLAU P00749 1/20 0.34
ALDH1A1 P00352 2/20 0.33
PARP15 Q460N3 2/20 0.33
PARP14 Q460N5 2/20 0.33
PARP10 Q53GL7 2/20 0.33
HSD17B10 Q99714 2/20 0.33
KMT2A Q03164 1/20 0.33
PARP16 Q8N5Y8 1/20 0.33
PARP11 Q9NR21 1/20 0.33
PARP4 Q9UKK3 1/20 0.33
TNKS O95271 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
PARP2 Q9UGN5 1/20 0.33
IP6K1 Q92551 1/20 0.33
KDM4E B2RXH2 1/20 0.33
BRD4 O60885 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3914969 0.84 KDM4E (0.42) SIRT2TSHRALDH1A1HSD17B10KDM4E
SCHEMBL4671199 0.79 CA1 (0.49) LCKALDH1A1HSD17B10KMT2AKDM4E
SCHEMBL28290680 0.76 LCK (0.37) LCKSIRT2PARP1TSHRPLAU
SCHEMBL1227619 0.76 LCK (0.34) LCKSIRT2PARP1TSHRALDH1A1
Carbamic Acid SCHEMBL28658378 0.74 MAPT (0.38) PARP1TSHRALDH1A1PARP10HSD17B10
SCHEMBL31750688 0.71 TSHR (0.38) LCKSIRT2PARP1TSHRALDH1A1
SCHEMBL2591105 0.71 CA2 (0.42) ALDH1A1HSD17B10KMT2AKDM4EMAPT
SCHEMBL27973449 0.71 TSHR (0.38) LCKSIRT2PARP1TSHRALDH1A1
SCHEMBL20822530 0.70 LCK (0.35) LCKSIRT2PARP1TSHRALDH1A1
SCHEMBL17476748 0.69 LCK (0.40) LCKPARP1TSHRALDH1A1PARP15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9321731-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-04-26 US claimed
US-20160031820-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-04 US claimed
EP-2268643-A1 DIOXOLANE AND DIOXOLANONE FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS Bristol-Myers Squibb Company (US) 2011-01-05 EP disclosed
WO-2009120890-A1 DIOXOLANE AND DIOXOLANONE FUSED INDOLOBENZADIAZEPINE HCV NS5B INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-10-01 WO disclosed
WO-2000073313-A1 NEW TRICYCLIC AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE ASTRAZENECA AB (SE) 2000-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031820-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC5, HDAC1 LCK 1388/4885SIRT2 33/4885PARP1 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.